Zymeworks Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, has announced its participation in two upcoming investor conferences. The company, which focuses on developing novel, multifunctional biotherapeutics for difficult-to-treat diseases, will be present at:

1. BTIG Virtual Biotechnology Conference on August 6, where management will engage in virtual one-on-one meetings and a fireside chat at 4:00 pm ET.

2. Wedbush PacGrow Healthcare Conference on August 13-14 in New York, NY. Here, Zymeworks will participate in a panel discussion titled 'ADCs and Old Lace: Antibody Drug Conjugates' on August 14 from 8:45 – 9:25 am ET, as well as one-on-one meetings throughout the event.

These conferences provide Zymeworks with opportunities to showcase their progress and engage with investors in the biotechnology sector.

VANCOUVER, British Columbia, July 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:

• BTIG Virtual Biotechnology Conference: Zymeworks’ management will participate in virtual one-on-one meetings and a fireside chat on Tuesday, August 6 at 4:00 pm Eastern Time (ET).
• Wedbush PacGrow Healthcare Conference: Zymeworks’ management will participate a panel discussion titled “ADCs and Old Lace: Antibody Drug Conjugates” taking place on August 14, between 8:45 – 9:25 am ET, and will participate in one-on-one meetings on August 13-14 in New York, NY.

About Zymeworks Inc.

Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates.  Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X. 

Contacts:

Investor Inquiries:

Shrinal Inamdar
Director, Investor Relations
(604) 678-1388 
ir@zymeworks.com 
investors@zymeworks.com

Media Inquiries:

Diana Papove
Senior Director, Corporate Communications
(604) 678-1388 
ir@zymeworks.com 
media@zymeworks.com

FAQ

What investor conferences will Zymeworks (ZYME) attend in August 2024?

Zymeworks (ZYME) will attend the BTIG Virtual Biotechnology Conference on August 6 and the Wedbush PacGrow Healthcare Conference on August 13-14, 2024.

What type of presentation will Zymeworks (ZYME) give at the BTIG Virtual Biotechnology Conference?

At the BTIG Virtual Biotechnology Conference, Zymeworks (ZYME) management will participate in virtual one-on-one meetings and a fireside chat on August 6 at 4:00 pm ET.

What panel will Zymeworks (ZYME) participate in at the Wedbush PacGrow Healthcare Conference?

Zymeworks (ZYME) will participate in a panel discussion titled 'ADCs and Old Lace: Antibody Drug Conjugates' at the Wedbush PacGrow Healthcare Conference on August 14, 2024, from 8:45 – 9:25 am ET.

Where will the Wedbush PacGrow Healthcare Conference be held for Zymeworks (ZYME)?

The Wedbush PacGrow Healthcare Conference, which Zymeworks (ZYME) will attend, will be held in New York, NY on August 13-14, 2024.